Repository logo
 

A review of the biological and potential therapeutic actions of harpagophytum procumbens

dc.contributor.authorMcBean, Douglas
dc.contributor.authorGrant, L.
dc.contributor.authorFyfe, Lorna
dc.contributor.authorWarnock, Mary
dc.date.accessioned2018-06-29T21:34:11Z
dc.date.available2018-06-29T21:34:11Z
dc.date.issued2007-11-24
dc.description.abstractHarpagophytum procumbens (Hp), commonly known as Devil's Claw is a perennial plant which thrives in arid conditions. For centuries, it has been used as a traditional treatment for a variety of illnesses, including fevers, skin complaints, arthritis and diseases of the digestive tract as well as an appetite stimulant. Since its introduction to Europe in the early twentieth century, it has become a popular antiinflammatory and analgesic preparation amongst herbalists for supportive or adjuvant treatment of degenerative joint diseases, tendonitis, headache, backache and menstrual pain. The validity of Hp as an effective antiinflammatory and analgesic preparation, particularly in the relief of arthritic symptoms, has been investigated in numerous animal, clinical and in vitro studies. Although some contradictory evidence exists, the majority of animal studies appear to indicate Hp as an effective antiinflammatory and analgesic preparation in the treatment of acute and subacute inflammation. Clinical trials support Hp as a beneficial treatment for the alleviation of pain and improvement of mobility in a variety of musculoskeletal conditions. Analysis of the in vitro and ex vivo studies that currently exist, indicate that Hp has significant effects on numerous proinflammatory markers. However, the exact mechanism(s) by which Hp may reduce inflammation remain to be elucidated.
dc.description.eprintid112
dc.description.facultysch_die
dc.description.ispublishedpub
dc.description.number3
dc.description.referencetextAndersen OML, Santos EH, Seabra LB, da Silva AA, Tufik S. 2004. Evaluation of acute and chronic treatments with Harpagophytum procumbens on Freund's adjuvant-induced arthritis in rats. J Ethnopharmacol 91: 325- 330. Arrigoni-Martelli E. 1977. Inflammation and Antiinflammatories. Spectrum Publications: New York. Baghdikian B, Lanhers MC, Fleurentin J et al. 1997. An analytical study, anti-inflammatory and analgesic effects of Harpagophytum procumbens and Harpagophytum zeyheri. Planta Med 63: 171-176. Belaiche P. 1982. tude clinique de 630 cas d'arthrose traits par le nbulisat aqueux d'Harpagophytum procumbens (Radix). Phytotherapy 1: 22-28. Benninger J, Schneider HT, Schuppan D, Kirchner T, Hahn EG. 1999. Acute hepatitis induced by greater celandine (Chelidonium majus). Gastroenterology 117: 1234-1237. Bermejo BP, D_az LAM, Silvn SAM et al. 2000. Effects of some iridoids from plant origin on arachidonic acid metabolism in cellular systems. Planta Med 66: 324-328. Betancor-Fernndez A, Prez-Glvez A, Sies H, Stahl W. 2003. Screening pharmaceutical preparations containing extracts of turmeric rhizome, artichoke leaf, devil's claw root and garlic or salmon oil for antioxidant capacity. J Pharm Pharmacol 55: 981-986. Bhattacharya A, Bhattacharya SK. 1998. Anti-oxidant activity of Harpagophytum procumbens (Devil's claw). Br J Phytother 5: 68 -71. Boje K, Lechtenberg M, Nahrstedt A. 2003. New and known iridoid- and phenylethanoid glycosides from Harpagophytum procumbens and their in vitro inhibition of human leukocyte elastase. Planta Med 69: 820- 825. Burger JFW, Brandt EV, Ferreira D. 1987. Iridoid and phenolic glycosides from Harpagophytum procumbens. Phytochemistry 26: 1453-1457. Chan TY. 2001. Interaction between warfarin and danshen (Salvia miltiorrhiza). Ann Pharmacother 35: 501-504. Chantre P, Cappelaere A, Leblan D, Geudon D, Vandermander J, Fournie B. 2000. Efficacy and tolerance of Harpagophytum procumbens versus diacerhein in treatment of osteoarthritis. Phytomedicine 7: 177-183. Chrubasik S, Junck H, Breitschwerdt H, Conradt C, Zappe H. 1999. Effectiveness of Harpagophytum extract WS 1531 in the treatment of exacerbation of low back pain: a randomised, placebo-controlled, double-blind study. Eur J Anaesthiol 16: 118-129. Chrubasik S, Kunzel O, Thanner J, Conradt C, Black A. 2005. A 1-year follow-up after a pilot study with Doloteffin for low back pain. Phytomedicine 12: 1-9. Chrubasik JE, Lindhorst E, Neumann E et al. 2006. Potential molecular basis of the chondroprotective effect of Harpagophytum procumbens. Phytomedicine 13: 598- 600. Chrubasik S, Model A, Black A, Pollack S. 2003. A randomized double-blind pilot study comparing Doloteffin and Vioxx in the treatment of low back pain. Rheumatology 42: 141- 148. Chrubasik S, Schmidt A, Junck H, Pfisterer M. 1997. Wirksamkeit und Wirkschaftlichkeit von Teulfelskrallenwurzelextrakt bie runkenschmerzen: Erst ergbnisse einer therapeutischen. Kohortenstudie Forsch Komplementarmed 332-336. Chrubasik S, Sporer F, Dillmann-Marschner R, Friedmann A, Wink M. 1999/2000. Physicochemical properties of harpagoside and its in vitro release from Harpagophytum procumbens extract tablets. Phytomedicine 6: 469-473. Chrubasik S, Thanner J, Kunzel O, Conradt C, Black A, Pollak S. 2002. Comparison of outcome measures during treatment with the proprietary Harpagophytum extract Doloteffin in patients with pain in the lower back, knee or hip. Phytomedicine 9: 181-194. Chrubasik S, Zimpfer CH, Schutt U, Ziegler R. 1996. Effectiveness of Harpagophytum procumbens in treatment of acute low back pain. Phytomedicine 3: 1-10. Eichler O, Koch C. 1970. Uber die antiphlogistische, analgetishche, and spasmolytische Wirksamkeit von Harpagophytum procumbens. Arzeimettelforsch Drug Res 20: 107- 109. Erdos A, Fontaine R, Friehe H, Durand R, Poppinghaus T. 1978. Contribution to the pharmacology of different extracts as well as the harpagoside from Harpagophytum procumbens DC. Planta Med 34: 97-108. Ernst E. 2000. Herbal medicines: where is the evidence? Br Med J 321: 395-396. ESCOP Scientific Committee. 2003. ESCOP Monographs. Harpagophyti radix. Thieme Press: Stuttgart, New York. Fiebich BL, Heinrich M, Hiller K-O, Kammerer N. 2001. Inhibition of TNF- synthesis in LPS-stimulated primary human monocytes by Harpagophytum extract SteiHap 69. Phytomedicine 8: 28-30. Fleurentin J, Mortier F. 1997. Entzuendungshemmende und analgetische Wirkungen von Harpagophytum procumbens and H. Zeyheri. In Rheumatatherapie mit Phytopharmaka, Chrubasik S, Wink M (eds). Hippocrates: Stuttgart, 68-76. Frerick H, Biller A, Schmidt U. 2001. Stufenschema bei coxarthrose. Der Kassenarzt 5: 34-41. Gagnier JJ, Chrubasik S, Manheimer E. 2004. Harpagophytum procumbens for osteoarthritis and low back pain: a systematic review. BMC Complement Altern Med 4: 13. Gobel H, Heinze A, Ingwersen M, Neiderberger U, Gerber D. 2001. Effects of Harpagophytum procumbens LI 174 (devil's claw) on sensory, motor and vascular muscle reagibility in the treatment of unspecific back pain. Schmerz 15: 10 -18. Goldring SR, Goldring MB. 2004. The role of cytokines in cartilage matrix degeneration in osteoarthritis. Clin Orthop Relat Res 427: S27-S36. Gordon DW, Rosenthal G, Hart J, Sirotta R, Baker AL. 1995. Chaparral ingestion: the broadening spectrum of liver injury caused by herbal medications. JAMA 273: 489- 490. Gorski JC, Huang S-M, Pinto A et al. 2004. The effect of Echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther 75: 89 -100. Grahame R, Robinson BV. 1981. Devils's claw (Harpagophytum procumbens): pharmacological and clinical studies. Ann Rheum Dis 40: 632. Gunther M, Schmidt PC. 2005. Comparison between HPLC and HPTLC-densitometry for the determination of harpagoside from Harpagophytum procumbens CO2-extracts. J Pharm Biomed Anal 37: 817-821. Guyader M. 1984. Les Plantes Antirheumatismales. tudes Historique et Pharmacologique, et Etude Clinique du Nbulisat d'Harpagophytum procumbens DC chez 50 Patients Arthrosiquws Suivis in Service Hospitalier [dissertation]. Universit Pierre et Marie Curie, Paris. Haag-Berrurier M, Kuballa B, Anton R. 1978. Dosage des glucoiridoides totaux dans la racine d'Harpagopytum procumbens DC und Harpagophytum zeheri DECNE. Planta Med 12: 197-206. Halliwell B, Hoult JR, Blake DR. 1988. Oxidants, inflammation, and anti-inflammatory drugs. FASEB J 2: 2867-2873. Harvey J, Colin-Jones DG. 1981. Mistletoe hepatitis. Br Med J 282: 186 -187. Huang TH, Tran VH, Duke RK et al. 2005. Harpagoside suppresses lipopolysaccharide-induced iNOS and COX-2 expression through inhibition of NF-kappa B activation. J Ethnopharmacol 104: 149-155. Jadot G, Lecomte A. 1992. Activite anti-inflammatoire d'Harpagophytum procumbens DC. Lyon Med Med Med Sud-Est 28: 833-835. Jang MH, Lim S, Han SM et al. 2003. Harpagophytum procumbens suppresses lipopolysaccharide-stimulated expressions of cyclooxygenase-2 and inducible nitric oxide synthase in fibroblast cell line L929. J Pharmacol Sci 93: 367-371. Jaswal S, Mehta HC, Sood AK, Kaur J. 2003. Antioxidant status in rheumatoid arthritis and role of antioxidant therapy. Clin Chim Acta 338: 123-129. Kaszkin M, Beck KF, Koch E et al. 2004. Downregulation of iNOS expression in rat mesangial cells by special extracts of Harpagophytum procumbens derives from harpagosidedependent and independent effects. Phytomedicine 11: 585- 595. Kemper KJ. 1999. Devils Claw (Harpagophytum procumbens). Longwood Herbal Task Force. http://www.longwoodherbal .org/devilsclaw/devilsclaw.pdf Kundu JK, Mossanda KS, Na H, Surh Y. 2005. Inhibitory effects of the extracts of Sutherlandia frutescens (L.) R. Br. and THERAPEUTIC ACTIONS OF HARPAGOPHYTUM PROCUMBENS 209 Harpagophytum procumbens DC. on phorbol ester-induced COX-2 expression in mouse skin: AP-1 and CREB as potential upstream targets. Cancer Lett 218: 21-31. Langmead L, Dawson C, Hawkins C, Banna N, Loo S, Rampton DS. 2002. Antioxidant effects of herbal therapies used by patients with inflammatory bowel disease: an in vitro study. Aliment Pharmacol Ther 16: 197-205. Lanhers MC, Fleurentin J, Mortier F, Vinche A, Younos C. 1992. Anti-inflammatory and analgesic effects of an aqueous extract of Harpagophytum procumbens. Planta Med 58: 117- 123. Laudahn D, Walper A. 2001. Efficacy and tolerance of Harpagophytum extract LI174 in patients with chronic non-radicular back pain. Phytother Res 15: 621-624. Lecomte A, Costa JP. 1992. Harpagophytum dans l'arthrose: Etudes en double insu contre placebo. 372 Le Magazine 15: 27-30. Loew D, Mollerfeld J, Schrodter A, Puttkammer S, Kaszkin M. 2001. Investigations on the pharmacokinetic properties of Harpagophytum extracts and their effects on eicosanoid biosynthesis in vitro and ex vivo. Clin Pharmacol Ther 69: 356-364. Mahomed IM, Ojewole JAO. 2004. Analgesic, antiinflammatory and antidiabetic properties of Harpagophytum procumbens DC (Pedaliaceae) secondary root aqueous extract. Phytother Res 18: 982-989. Mahomed IM, Ojewole JAO. 2006. Anticonvulsant activity of Harpagophytum procumbens DC [Pedaliaceae] secondary root aqueous extract in mice. Brain Res Bull 69: 57-62. Manez S, Alcaraz MJ, Pay M, Rios JL, Hancke JL. 1990. Selected extracts from medicinal plants as anti-inflammatory agents. Planta Med 56: 656. McLeod DW, Revell P, Robinson BV. 1979. Investigations of Harpagophytum procumbens (Devil's Claw) in the treatment of experimental inflammation and arthritis in the rat. Br J Pharmacol 66: 140-141. Mills S, Bone K. 2000. Principles and Practice of Phytotherapy. Harcourt Publishers Ltd: London. Miskelly FG, Goodyer LI. 1992. Hepatic and pulmonary complications of herbal medicine. Postgrad Med 68: 935- 936. Moussard C, Alber D, Toubin MM, Thevenon N, Henry JC. 1992. A drug used in traditional medicine, Harpagophytum procumbens: no evidence for NSAID-like effect on whole blood eicosanoid production in human. Prostaglandins Leukot Essent Fatty Acids 46: 283-286. Mukherjee D, Nissen SE, Topol EJ. 2001. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286: 954-959. Page CP, Curtis MJ, Sutter MC, Walker MJA, Hoffman BB. 1997. Integrated Pharmacology. Mosby: London. Pinget M, Lecomte A. 1997. Die Wirkung der Harpagophytum Arkocaps' bei degenerativem Rheuma. Naturheilpraxis 50: 267-269. Rang HP, Dale MM, Ritter JM, Moore PK. 2003. Pharmacology, 5th edn. Churchill Livingstone: Edinburgh. Schruffler H. 1980. Salus Teufelskralle-Tabletten. Ein fortschritt in der nicht steroidalen antirheumatischen therapie. Die Medizinische Publikation: 1- 8. Schulze-Tanzil G, Hansen C, Shakibaei M. 2004. Effect of a Harpagophytum procumbens DC extract on matrix metalloproteinases in human chondrocytes in vitro. Arzneimittelforschung 45: 213-220. Soulimani R, Younos C. 1994. The role of stomachal digestion on the pharmacological activity of plant extracts, using as an example extracts of Harpagophytum procumbens. Can J Physiol Pharmacol 72: 1532-1536. Tippler B, Syrovets T, Plaza N, Loew D, Simmet T. 1997. Harpagophytum procumbens DC used in traditional medicine inhibits eicosanoid biosynthesis in human whole blood. Int J Tiss React 19: 101-102. Tyler VE. 1993. The Honest Herbal. Pharmaceutical Products Press: New York. Unger M, Frank A. 2004. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/ mass spectrometry and automated online extraction. Rapid Commun. Mass Spectrom 18: 2273-2281. Velpandian T, Jasuja R, Bhardwaj RK, Jaiswal J, Gupta SK. 2001. Piperine in food: interference in the pharmacokinetics of phenytoin. Eur J Drug Metab Pharmacokinet 26: 241-247. Wegener T. 2000. Devil's Claw: from African traditional remedy to modern analgesic and antiinflammatory. Herbal Gram 50: 47-54. Wegener T, Lupke NP. 2003. Treatment of patients with arthrosis of hip or knee with an aqueous extract of Devil's Claw (Harpagophytum procumbens, DC). Phytother Res 17: 1165- 1172. Whitehouse LW, Znamirowska M, Paul CJ. 1983. Devil's Claw (Harpagophytum procumbens): no evidence for antiinflammatory activity in the treatment of arthritic disease. Can Med Assoc J 129: 249-251. Whiting PW, Clouston A, Kerlin P. 2002. Black cohosh and other herbal remedies associated with acute hepatitis. Med J Aust 177: 440-443. Zorn B. 1958. Uber die antiarthritische Wirkung der Harpagophytum Wurtzel: vorlaufige Mittleilung. Z Rheumatol 17: 134-138.
dc.description.statuspub
dc.description.volume21
dc.format.extent199-209
dc.identifierER112
dc.identifier.citationMcBean, D., Grant, L., Fyfe, L. & Warnock, M. (2007) A review of the biological and potential therapeutic actions of harpagophytum procumbens. Phytotherapy Research, 21(3), pp. 199-209.
dc.identifier.doi10.1002/ptr.2029
dc.identifier.issn0951-418X
dc.identifier.urihttps://doi.org/10.1002/ptr.2029
dc.identifier.urihttps://eresearch.qmu.ac.uk/handle/20.500.12289/112
dc.publisherJohn Wiley & Sons, Ltd
dc.relation.ispartofPhytotherapy Research
dc.subjectHarpagophytum Procumbens
dc.subjectDevil's Claw
dc.subjectAntiinflammatory
dc.titleA review of the biological and potential therapeutic actions of harpagophytum procumbens
dc.typearticle
dcterms.accessRightsnone
qmu.authorWarnock, Mary
qmu.authorMcBean, Douglas
qmu.authorFyfe, Lorna
rioxxterms.typearticle

Files